期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

乳腺癌患者HER2基因表达状态及临床病理意义探讨

下载PDF
导出
摘要 人类表皮生长因子受体2（HER2）定位于17号染色体q12-21,是具有酪氨酸激酶活性的跨膜生长因子受体。乳腺癌HER2基因扩增或蛋白过表达,与疾病进展和预后相关。目前临床上选用免疫组织化学（immunohistochemistry,IHC）法进行筛查,
作者 邓明凤 王昌富 郭华雄 陈登峰 黄俊 李滔
机构地区 华中科技大学同济医学院附属荆州医院检验医学部 华中科技大学同济医学院附属荆州医院病理科 华中科技大学同济医学院附属荆州医院乳腺科
出处 《中国实验诊断学》 北大核心 2011年第2期330-332,共3页 Chinese Journal of Laboratory Diagnosis
关键词 乳腺癌患者 临床病理 HER2 人类表皮生长因子受体 基因表达 状态 17号染色体 免疫组织化学
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献9

  • 1Watters AD,Going JJ,Cooke TG,et a1.Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma[J].Breast Cancer Res Treat,2003,77(2):109.
  • 2Risio M,Casorzo L,Redana S,et a1.HER2 gene-amplified breast cancers with monosomy of chromosome 17 are poorly responsive to trastuzumab-based treatment[J].Oncol Rep,2005,13(2):305.
  • 3Wong SW,Rangan AM,Bilous AM,et al.The value of S-phase and DNA ploidy analysis as prognostic markers for node-negative breast cancer in the Australian setting[J].Pathology,1999,31(2):90.
  • 4<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量：164
  • 5Press MF,Sauter G,Bernstein L,et al.Diagnostic evaluation of HER-2 as a molecular target:an assessment of accuracy and reproducibility of laboratory testing in large,prospective,randomized clinical trials[J].Clin Cancer Res,2005,11(18):6598.
  • 6曾瑄,梁智勇,武莎斐,周炜洵,高洁,刘彤华.乳腺癌HER2蛋白表达阳性者的基因状态分析[J].中华病理学杂志,2006,35(10):584-588. 被引量：40
  • 7Hammock L,Lewis M,Phillips C,et al.Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization[J].Hum Pathol,2003,34(10):1043.
  • 8Wang S,Hossein Saboorian M,Frenkel EP,et al.Aneusomy 17 in breast cancer:its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status[J].Mod Pathol,2002,15(2):137.
  • 9陈红,许建平,马小干,程应东,杨桦,孙建国,陈正堂.乳腺癌HER2基因表达阳性者17号染色体倍体性与HER2蛋白表达及临床预后因素的相关性分析[J].重庆医学,2009,38(7):803-804. 被引量：9

二级参考文献33

  • 1曾瑄,赵大春,周炜洵,武莎斐,梁智勇,刘彤华.荧光原位杂交检测乳腺癌HER2基因状态[J].中华病理学杂志,2005,34(11):701-705. 被引量：65
  • 2曾瑄,梁智勇,武莎斐,周炜洵,高洁,刘彤华.乳腺癌HER2蛋白表达阳性者的基因状态分析[J].中华病理学杂志,2006,35(10):584-588. 被引量：40
  • 3Takehisa M, Sasa M, Bando Y, et al. Chromosomal aneusomy (ehr 1,11,17) detected by fluorescence in situ hybridization may be a prognostic factor in breast cancer [J]. Anticancer Res,2007,27(2) : 1073.
  • 4Mottolese M, Orlandi G, Sperduti I, et al. Bio-pathologic characteristics related to chromosome 11 aneusomy and cyclin D1 gene status in surgically resected stage Ⅰ and Ⅱ breast cancer: Identification of an adverse prognostic profile[J]. Am J Surg Pathol,2007,31(2) :247.
  • 5Wong SW, Rangan AM,Bilons AM,et al. The value of sphase and DNA ploidy analysis as prognostic markers for node-negative breast cancer in the austrifian setting[J]. Pathology, 1999,31 (2) : 90.
  • 6Prati R, Apple SK, He J, et al. Histopathologic characteristics predicting HER-2/ neu amplification in breast cancer[J]. Breast J,2005,11(6) :33.
  • 7Watters AD,Going J J, Cooke TG, et al. Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma [J]. Breast Cancer Research Treatment, 2003,77 : 109.
  • 8Wang S, Hossein Saboorian M, Frenkel EP, et al. Aneusomy 17 in breast cancer:its role in HER2/neu protein expression and implication for clinical assessment of HER2/ neu status[J]. Mod Pathol, 2002,15 (2) : 137.
  • 9Hammock L, Lewis M, Phillips C, et al. Strong HER2/ neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization [J]. Hum Pathol, 2003, 34 (10):1043.
  • 10Yaziji H,Goldstein LC,Barry TS,et al.HER-2 testing in breast cancer using parallel tissue-based methods.JAMA,2004,291:1972-1977.

共引文献200

中国实验诊断学
2011年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部